Mucopront (Carbocisteine)

Carbocisteine, the active ingredient in Mucopront, is a mucolytic presented as an oral formulation for oral use. It reduces the thickness of mucus, facilitating clearance in patients with chronic bronchitis, chronic obstructive pulmonary disease, and respiratory infections characterized by thick sputum.

GNH USA supplies Mucopront as a licensed, GDP‑compliant international pharmaceutical supplier, ensuring quality and regulatory compliance while serving hospitals, pharmacies and clinics worldwide. The company leverages a global logistics network to deliver products promptly and safely across EU and other markets.

Carbocisteine is used as a mucolytic to improve mucus clearance in several respiratory conditions. - Chronic bronchitis: reduces sputum viscosity, making it easier to expectorate and decreasing cough frequency. - Chronic obstructive pulmonary disease (COPD): helps clear airway secretions, improves airflow and may reduce exacerbation severity. - Respiratory tract infections with thick mucus: facilitates removal of mucus, supporting airway patency and aiding recovery.

Carbocisteine may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Abdominal pain: discomfort in the abdomen. - Dizziness: transient light‑headedness. Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or jaundice.

When prescribing carbocisteine, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function. - Hepatic disease: use cautiously in patients with liver disorders and monitor liver enzymes. - Concomitant antitussives: avoid combining with suppressants of cough as mucus clearance may be hindered. - Asthma: monitor for bronchospasm, especially in patients with reactive airway disease. - Pregnancy and lactation: assess risk‑benefit, as safety data are limited. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Carbocisteine can interact with certain medicines, affecting either its efficacy or the safety profile of the co‑administered drug. Major Interactions (Avoid): - Other mucolytics: combined use may increase gastrointestinal irritation. - Nitrofurantoin: carbocisteine may reduce its antibacterial activity. Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., azithromycin): monitor for increased GI upset. - Anticoagulants (e.g., warfarin): observe INR as mucolytics can affect plasma protein binding. - Bronchodilators (e.g., beta‑agonists): assess for additive cough suppression. - Antihistamines: watch for enhanced sedation or dizziness.